Lymphoma Vaccine Extends Survival in Late-stage Study

Researchers at the University of Texas MD Anderson Cancer Center say a Phase III trial of the therapeutic vaccine BioVaxID for follicular lymphoma increased disease-free survival by 14 months.

The study included 234 patients whose disease went into remission following chemotherapy. Those who received BioVaxID experienced a median time to relapse of 44.2 months, as compared to just 30.6 months in patients who didn't get the vaccine. Additionally, researchers found that patients with a certain biological marker survived almost 53 months